Major report reveals problems with EU Clinical Trials Directive
This article was originally published in SRA
Executive Summary
The European Clinical Trials Directive, which came into force in 2004 with the goal of harmonising the clinical research environment throughout the European Union, has made it more complicated for sponsors to conduct multinational clinical trials. It has also increased the administrative burden for competent authorities evaluating and supervising clinical trial authorisations. These are just two of many findings from a major EU-sponsored project set up to examine how the directive (2001/20/EC) has affected pharmaceutical research in the EU1,2.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.